S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.49 (+1.86%)
AAPL   111.97 (+1.72%)
MSFT   207.39 (+2.39%)
FB   254.36 (+2.50%)
GOOGL   1,459.03 (+2.02%)
AMZN   3,124.98 (+5.56%)
NVDA   504.82 (+0.82%)
TSLA   425.68 (-5.28%)
BABA   275.40 (+0.58%)
CGC   16.01 (+1.72%)
GE   6.23 (-1.89%)
MU   49.62 (+0.96%)
AMD   77.62 (-0.41%)
T   28.50 (-0.45%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.99 (+0.75%)
DIS   127.08 (+1.33%)
BAC   23.87 (-2.45%)
BA   156.89 (+0.35%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.49 (+1.86%)
AAPL   111.97 (+1.72%)
MSFT   207.39 (+2.39%)
FB   254.36 (+2.50%)
GOOGL   1,459.03 (+2.02%)
AMZN   3,124.98 (+5.56%)
NVDA   504.82 (+0.82%)
TSLA   425.68 (-5.28%)
BABA   275.40 (+0.58%)
CGC   16.01 (+1.72%)
GE   6.23 (-1.89%)
MU   49.62 (+0.96%)
AMD   77.62 (-0.41%)
T   28.50 (-0.45%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.99 (+0.75%)
DIS   127.08 (+1.33%)
BAC   23.87 (-2.45%)
BA   156.89 (+0.35%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.49 (+1.86%)
AAPL   111.97 (+1.72%)
MSFT   207.39 (+2.39%)
FB   254.36 (+2.50%)
GOOGL   1,459.03 (+2.02%)
AMZN   3,124.98 (+5.56%)
NVDA   504.82 (+0.82%)
TSLA   425.68 (-5.28%)
BABA   275.40 (+0.58%)
CGC   16.01 (+1.72%)
GE   6.23 (-1.89%)
MU   49.62 (+0.96%)
AMD   77.62 (-0.41%)
T   28.50 (-0.45%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.99 (+0.75%)
DIS   127.08 (+1.33%)
BAC   23.87 (-2.45%)
BA   156.89 (+0.35%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.49 (+1.86%)
AAPL   111.97 (+1.72%)
MSFT   207.39 (+2.39%)
FB   254.36 (+2.50%)
GOOGL   1,459.03 (+2.02%)
AMZN   3,124.98 (+5.56%)
NVDA   504.82 (+0.82%)
TSLA   425.68 (-5.28%)
BABA   275.40 (+0.58%)
CGC   16.01 (+1.72%)
GE   6.23 (-1.89%)
MU   49.62 (+0.96%)
AMD   77.62 (-0.41%)
T   28.50 (-0.45%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.99 (+0.75%)
DIS   127.08 (+1.33%)
BAC   23.87 (-2.45%)
BA   156.89 (+0.35%)
Log in
LON:FAB

Fusion Antibodies Share Forecast, Price & News

GBX 197.50
+15.00 (+8.22 %)
(As of 09/21/2020 12:00 AM ET)
Add
Compare
Today's Range
140
Now: GBX 197.50
205
50-Day Range
80
MA: GBX 95.53
182.50
52-Week Range
55
Now: GBX 197.50
230
Volume462,941 shs
Average Volume35,274 shs
Market Capitalization£50.24 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases. The company offers antibody identification and discovery services; and a range of antibody engineering services for various stages of therapeutic and diagnostic antibody development. It also engages in the humanization of monoclonal antibodies. In addition, the company provides antibody sequencing services; custom expression and purification of recombinant proteins; transient protein expression; and stable cell line development services, as well as antibody analysis services. It serves pharmaceuticals, biotech, and diagnostic companies worldwide. The company has a collaboration partnership with Celonic AG for the development of high yield stable cell lines. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-28-90432800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£3.90 million
Cash FlowGBX 16.26 per share
Book ValueGBX 21.80 per share

Profitability

Miscellaneous

Employees22
Market Cap£50.24 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 197.50
+15.00 (+8.22 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FAB News and Ratings via Email

Sign-up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fusion Antibodies (LON:FAB) Frequently Asked Questions

How has Fusion Antibodies' stock been impacted by Coronavirus (COVID-19)?

Fusion Antibodies' stock was trading at GBX 67.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FAB shares have increased by 192.6% and is now trading at GBX 197.50.
View which stocks have been most impacted by COVID-19
.

Who are some of Fusion Antibodies' key competitors?

What other stocks do shareholders of Fusion Antibodies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Antibodies investors own include Aminex (AEX), D4t4 Solutions (D4T4), Snap-on (SNA), Asian Television Network International (SAT), Lockheed Martin (LMT), Blockchain Worldwide (BLOC) and ABM Industries (ABM).

Who are Fusion Antibodies' key executives?

Fusion Antibodies' management team includes the following people:
  • Dr. Paul Gerard Kerr, CEO & Director (Age 47)
  • Mr. James Fair, CFO, Company Sec. & Director (Age 53)
  • Dr. Richard John Buick, CTO & Director (Age 42)
  • Prof. Jim Johnston, Founder

What is Fusion Antibodies' stock symbol?

Fusion Antibodies trades on the London Stock Exchange (LON) under the ticker symbol "FAB."

How do I buy shares of Fusion Antibodies?

Shares of FAB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Fusion Antibodies' stock price today?

One share of FAB stock can currently be purchased for approximately GBX 197.50.

How big of a company is Fusion Antibodies?

Fusion Antibodies has a market capitalization of £50.24 million and generates £3.90 million in revenue each year. Fusion Antibodies employs 22 workers across the globe.

What is Fusion Antibodies' official website?

The official website for Fusion Antibodies is fusionantibodies.com.

How can I contact Fusion Antibodies?

Fusion Antibodies' mailing address is Springbank Industrial Estate 1 Springbank Road, BELFAST, NIR BT17 0QL, United Kingdom. The company can be reached via phone at +44-28-90432800.

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.